Zimbabwe has declined a substantial American health deal worth $367m (£272m) spanning five years over the United States' insistence on sensitive information.
This move became public after a internal memorandum dated December was disclosed, which showed Head of State Emmerson Mnangagwa felt the deal was "skewed".
A government spokesperson later clarified that the United States was seeking genetic material for scientific study and profit while refused to share the benefits from any future medical innovations.
"We will now turn to the difficult and regrettable process of scaling back our support in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy said the US had provided more than $1.9bn for health programmes to Zimbabwe over the last twenty years.
A physicians' group in Zimbabwe has called for further talks to find a deal suitable to both sides so the nation's vital HIV programme can be sustained.
Broader Background
This rejection follows a similar situation in Kenya, where a high court halted a similar health funding agreement after concerns were raised about the security of Kenyans' health data.
Since returning to office recently, US President Donald Trump has drastically cut overseas assistance and closed the key foreign aid agency.
The agency had administered aid for the American government, but Trump claimed its expenditure was "wasteful" and his administration was pursuing government-to-government deals to enhance openness and accountability.
According to reports, 16 African countries have so far agreed to these new agreements, constituting over $18.3bn in committed funds.
Specifics of the Declined Deal
This assistance for Zimbabwe would have gone towards "tackling HIV/Aids, TB, malaria, maternal and child health, and disease outbreak preparedness.
"We are confident this cooperation would have delivered immense benefits for Zimbabwean communities, especially the 1.2 million men, women and children presently receiving antiretroviral therapy through American-funded initiatives," Tremont said.
However, government spokesperson Nick Mangwana argued the proposed deal was "unfair".
"The proposal required Zimbabwe to provide its biological resources and data over an extended period, with no corresponding promise of benefiting from any scientific breakthroughs – like new medicines or tests – that might be developed from that provided information," Mangwana explained.
"Effectively, our nation would supply the raw materials for medical research without any assurance that the final treatments would be available to our citizens should a future disease outbreak arise."
National Interest and Global Health
He also said that the US's withdrawal from the global health body and its push of one-on-one health agreements were undermining systems previously set up via the global organization.
The spokesperson cited its Pandemic Benefit-Sharing scheme designed to manage future pandemics.
"This framework is intended to guarantee that when a country contributes its information, the benefits – such as medicines and cures – are shared equitably, not monopolised solely by those with the capability to develop them."
These objections over the US deal "are not meant as anti-American sentiment," Mangwana stressed.
"We welcome continued dialogue with our American counterparts on how subsequent co-operation might be structured in a manner that respects the independence and dignity of both nations."
Medical Community Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) stated it acknowledged the official position, but recommended that negotiations need to persist given that much of the nation's Aids initiatives relied on external financing.
"If specific concerns arise, such as those relating to data governance or agreement terms, these can frequently be resolved via technical clarification and mutually agreed protections," it commented.
The situation underscores the ongoing tensions between accepting much-needed foreign assistance and protecting national sovereignty in an increasingly data-driven world.